New Delhi: Eli Lilly has announced the launch of its registered diabetic injection Byetta (exenatide injection) in India.

The drug treats patients with Type2 diabetes, as part of the prescription with two common oral diabetes medications, metformin and / or sulphonylureas.

Exenatide is the first in a new class of anti-diabetic medicines known as incretin mimetics and is the first FDA-approved agent of this category, a company statement quoted Sandeep Gupta, CMD, Lilly India, as saying. The statement hails Byetta as a novel approach to treating type 2 diabetes.